25 November 2020

DNS 10820


A new drug belonging to the family of indolic derivatives of the tryptophan metabolism for the treatment of immune dysreactive disorders, including inflammatory and infectious diseases. Encouraging results have been obtained in vivo efficacy studies and currently ADIENNE is actively working in its development.